ArticleTargeted oncology2023

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.

Karolina Piejko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.